Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues
- PMID: 19641523
- DOI: 10.1038/leu.2009.142
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues
Abstract
Ph-positive chronic myeloid leukemia (CML) and Ph-negative chronic myeloproliferative diseases (MPDs), characterized in many cases by the presence of the JAK2(V617F) mutation, have many features in common and yet also show fundamental differences. In this review, we pose five discrete and related questions relevant to both categories of hematological malignancy, namely: What are the mechanisms that underlie disease progression from a relatively benign or chronic phase? By what therapeutic methods might one target residual leukemia stem cells in CML? Is JAK2(V617F) the original molecular event in MPD? What epigenetic events must have a role in dictating disease phenotype in MPDs? And finally, Will the benefits conferred by current or future JAK2(V617F) inhibitors equal or even surpass the clinical success that has resulted from the use of tyrosine kinase inhibitors in CML? These and others questions must be addressed and in some cases should be answered in the foreseeable future.
Similar articles
-
The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. doi: 10.1055/s-2006-942754. Semin Thromb Hemost. 2006. PMID: 16810609 Review.
-
Kinase drug discovery approaches in chronic myeloproliferative disorders.Oncogene. 2009 Jun 18;28(24):2305-13. doi: 10.1038/onc.2009.107. Epub 2009 May 4. Oncogene. 2009. PMID: 19421140 Review.
-
New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):341-51. doi: 10.1055/s-2006-942755. Semin Thromb Hemost. 2006. PMID: 16810610 Review.
-
JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.Pathol Biol (Paris). 2011 Aug;59(4):e89-92. doi: 10.1016/j.patbio.2009.06.005. Epub 2009 Nov 24. Pathol Biol (Paris). 2011. PMID: 19939582
-
Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.Pathobiology. 2007;74(2):72-80. doi: 10.1159/000099120. Pathobiology. 2007. PMID: 17587878 Review.
Cited by
-
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Ther Adv Hematol. 2011 Feb;2(1):21-32. doi: 10.1177/2040620710394474. Ther Adv Hematol. 2011. PMID: 23556073 Free PMC article.
-
LIF, a Novel STAT5-Regulated Gene, Is Aberrantly Expressed in Myeloproliferative Neoplasms.Genes Cancer. 2011 May;2(5):593-6. doi: 10.1177/1947601911420139. Genes Cancer. 2011. PMID: 21901172 Free PMC article.
-
Successful transplantation of ethnically mismatched cord blood in a boy with atypical chronic myeloid leukemia.Int J Hematol. 2013 Jan;97(1):144-6. doi: 10.1007/s12185-012-1251-2. Epub 2012 Dec 22. Int J Hematol. 2013. PMID: 23264127
-
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.Leukemia. 2010 Sep;24(9):1545-54. doi: 10.1038/leu.2010.143. Epub 2010 Jun 24. Leukemia. 2010. PMID: 20574455 Free PMC article. Review.
-
Stem cell quiescence.Clin Cancer Res. 2011 Aug 1;17(15):4936-41. doi: 10.1158/1078-0432.CCR-10-1499. Epub 2011 May 18. Clin Cancer Res. 2011. PMID: 21593194 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
